MicroRNA-23b: Roles, functions and mechanisms in tumor
MicroRNAs are a class of non-coding short-stranded RNAs with important biological roles as post-transcriptional regulators of gene expression, involved in a variety of biological processes, such as cell growth, apoptosis, and angiogenesis. miR-23b, a well-studied miRNA, is aberrantly expressed in a variety of cancers. In this paper, we used the literature review method to sort out the biological roles and regulation of miR-23b in different types of cancers, including digestive system cancers, reproductive system cancers, head and neck cancers, genitourinary system cancers, and lung cancers. The data show that miR-23b can target both oncogenes and tumor suppressors, and its expression regulation in different types of cancers shows heterogeneity, which mainly acts through affecting signaling pathways, such as Wnt/β-catenin for tumorigenesis, and apoptotic proteins, such as BCL2 or oncogenes. The expression of miR-23b is closely related to the overall survival rate, disease-free survival rate, and prognosis in many cancers. Meanwhile, various in vivo and ex vivo studies have shown that miR-23b is a potential therapeutic target for cancer. It is important to understand the relationship between miR-23b and cancer development. miR-23b has the potential to serve as a clinically relevant molecular biomarker for cancer prognosis/diagnosis as well as a potential therapeutic target.
Authors
- Xueer Zheng (ORCID: https://orcid.org/0000-0001-5141-9141)
- Minhe Shen (ORCID: https://orcid.org/0000-0001-7321-3830)
- Shanming Ruan (ORCID: https://orcid.org/0000-0003-1061-5255)
- Xinyu Cai (ORCID: https://orcid.org/0009-0002-9611-6237)
- Zhenru Wang (ORCID: https://orcid.org/0000-0002-6101-8939)
- Jiong Mao
Institutions
- Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Genes & Diseases
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.gendis.2025.101853
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00